Clinical Edge Journal Scan

Higher BMI linked to risk for second primary cancer in breast cancer survivors


 

Key clinical point: Increasing body mass index (BMI) among survivors of early breast cancer is associated with a higher risk of developing a second primary cancer.

Major finding: At a mean follow-up of 88.0 months, 12.7% of patients developed a second primary cancer. For every 5 kg/m 2 increase in the BMI, the risk for any second cancer diagnosis increased by 7% and for obesity-related cancers by 13%. The risk for a second breast cancer and second estrogen receptor-positive breast cancer increased by 11% and 15%, respectively, for every 5 kg/m 2 increase in the BMI.

Study details: A retrospective cohort study of 6,481 women with early-stage primary breast cancer, wherein 33.4% of patients were overweight, and 33.8% were obese.

Disclosures: This work was supported in part by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics of the US National Cancer Institute, and American Cancer Society. The authors disclosed no conflict of interests.

Source: Feigelson HS et al. J Natl Cancer Inst. 2021 Apr 5. doi: 10.1093/jnci/djab053.

Recommended Reading

Quicker fertility rebound in young women with breast cancer
MDedge Hematology and Oncology
Cell-free DNA improves response prediction in breast cancer
MDedge Hematology and Oncology
FDA panel backs atezolizumab for mTNBC – at least for now
MDedge Hematology and Oncology
AHA statement flags CV risk of hormonal cancer therapies
MDedge Hematology and Oncology
TNBC: Sacituzumab govitecan extends survival
MDedge Hematology and Oncology
Breast cancer: IOERT boost noninferior to EBRT in terms of local control
MDedge Hematology and Oncology
Pembrolizumab plus eribulin shows activity in HR+, HER2-negative breast cancer
MDedge Hematology and Oncology
Breast cancer: Detrimental effects of adjuvant chemotherapy on QoL in older patients subside after 3 years
MDedge Hematology and Oncology
Metastatic breast cancer: Add-on alisertib shows survival benefit
MDedge Hematology and Oncology
Overtreatment does not benefit older patients with early ER+ breast cancer
MDedge Hematology and Oncology